Role of oxidative stress in intrauterine growth restriction
Role of oxidative stress in intrauterine growth restriction
复制标题
DOI：
10.1159/000106488
复制
发表时间：
2007-01-01
影响因子：
2.1
通讯作者：
Durak, Ilker
中科院分区：
文献类型：
--
作者：
Biri, Aydan;Bozkurt, Nuray;Durak, Ilker
目的：本研究的目的是确定氧化应激在胎儿宫内生长受限（IUGR）中的作用，并探讨导致IUGR中氧化应激的可能分子机制。
方法：对胎儿宫内生长受限孕妇的母体血浆、脐带血和胎盘组织中的氧化和抗氧化系统参数进行评估。从正常妊娠妇女中获取相同样本并进行评估。
结果：本研究结果表明，与对照组相比，胎儿宫内生长受限患者的母体血浆、脐带血浆和胎盘组织中丙二醛（MDA）和黄嘌呤氧化酶（XO）水平较高[MDA分别为：142.8 ± 18.0对86.4 ± 22.5 nmol/ml，151.6 ± 25.8对93.3 ± 7.4 nmol/ml，以及0.72 ± 0.19对0.42 ± 0.09 nmol/mg蛋白（所有p < 0.0005）；XO分别为：1.251 ± 0.674对0.20 ± 0.019 mIU/ml（p < 0.0005），1.97 ± 0.73对0.237 ± 0.143 mIU/ml（p < 0.0005），以及0.023 ± 0.0012对0.012 ± 0.004 mIU/ml（p < 0.025）]，而胎儿宫内生长受限患者的母体血浆、脐带血浆和胎盘组织中的抗氧化能力水平较低：分别为63.3 ± 11.9对198.0 ± 31.9 U/ml（p < 0.0005），32.6 ± 3.7对206.5 ± 27.1 U/ml（p < 0.0005），以及0.56 ± 0.23对1.16 ± 0.29 U/ml（p < 0.0005）。另一方面，胎儿宫内生长受限患者的腺苷脱氨酶活性在母体血浆（204.8 ± 103.5对115.6 ± 31.8 U/l，p < 0.01）和脐带血样本（584.2 ± 285.2对147.9 ± 44.8 U/l，p < 0.0005）中高于对照组，这可能表明氧化应激在胎儿宫内生长受限中起作用。此外，在母体血浆（128.2 ± 37.4对88.8 ± 16.6 U/ml，p < 0.005）和脐带血（162.1 ± 37.0对116.6 ± 20.7 U/ml，p < 0.005）中检测到超氧化物歧化酶活性增加，在母体血浆（1.83 ± 0.26对1.47 ± 0.31 IU/ml，p < 0.01）和胎盘组织（0.007 ± 0.0015对0.003 ± 0.0012 IU/ml，p < 0.0005）中检测到谷胱甘肽过氧化物酶活性增加，而在胎儿宫内生长受限组中，脐带血（23717 ± 3538对16397 ± 2771 IU/ml，p < 0.0005）和胎盘组织（47.2 ± 17.2对70.7 ± 11.3 IU/ml，p < 0.005）中过氧化氢酶活性降低。
结论：根据本研究结果，可以说胎儿宫内生长受限患者的氧化应激增加。为高危患者提供抗氧化剂可能对胎儿宫内生长受限的预防或治疗有用，尽管这是一种治疗结果不确定的疾病。版权所有（c）2007 S. Karger AG，巴塞尔。
Aims: The objectives of this study were to determine the role of oxidative stress in intrauterine growth restriction ( IUGR) and to investigate the possible molecular mechanism(s) leading to oxidant stress in IUGR. Methods: Parameters of the oxidative and antioxidant system were evaluated in maternal plasma, umbilical cord blood, and placental tissue of pregnant women with IUGR fetuses. The same samples were obtained from women with normal pregnancies and were evaluated. Results: The results of this study indicate that while the levels of malondialdehyde (MDA) and xanthine oxidase (XO) were higher in maternal plasma, umbilical cord plasma, and placental tissues of the patients with IUGR when compared to the control group [ MDA: 142.8 +/- 18.0 vs. 86.4 +/- 22.5 nmol/ ml, 151.6 +/- 25.8 vs. 93.3 +/- 7.4 nmol/ ml, and 0.72 +/- 0.19 vs. 0.42 +/- 0.09 nmol/ mg protein, respectively ( for all p < 0.0005); XO: 1.251 +/- 0.674 vs. 0.20 +/- 0.019 mIU/ ml ( p < 0.0005), 1.97 +/- 0.73 vs. 0.237 +/- 0.143 mIU/ ml ( p < 0.0005), and 0.023 +/- 0.0012 vs. 0.012 +/- 0.004 mIU/ ml ( p < 0.025), respectively], the levels of antioxidant potential were identified to be lower in maternal plasma, umbilical cord plasma, and placental tissues of the patients with IUGR: 63.3 +/- 11.9 vs. 198.0 +/- 31.9 U/ml ( p < 0.0005), 32.6 +/- 3.7 vs. 206.5 +/- 27.1 U/ ml ( p < 0.0005), and 0.56 +/- 0.23 vs. 1.16 +/- 0.29 U/ ml ( p < 0.0005), respectively. On the other hand, the activities of adenosine deaminase of the IUGR patients were higher than those of the control group in maternal plasma ( 204.8 +/- 103.5 vs. 115.6 +/- 31.8 U/ l, p < 0.01)and umbilical cord blood samples ( 584.2 +/- 285.2 vs. 147.9 +/- 44.8 U/ l, p < 0.0005) which may suggest that oxidative stress has a role in IUGR. Moreover, an increased superoxide dismutase activity in maternal plasma ( 128.2 +/- 37.4 vs. 88.8 +/- 16.6 U/ ml, p < 0.005) and cord blood ( 162.1 +/- 37.0 vs. 116.6 +/- 20.7 U/ ml, p < 0.005) and an increased glutathione peroxidase activity in maternal plasma ( 1.83 +/- 0.26 vs. 1.47 +/- 0.31 IU/ ml, p < 0.01) and placental tissue ( 0.007 +/- 0.0015 vs. 0.003 +/- 0.0012 IU/ ml, p < 0.0005) were detected, while decreased catalase activities in cord blood ( 23,717 8 3,538 vs. 16,397 8 2,771 IU/ ml, p < 0.0005) and placental tissue ( 47.2 +/- 17.2 vs. 70.7 +/- 11.3 IU/ ml, p < 0.005) were identified in IUGR groups. Conclusions: In the light of the results of this study, it can be stated that the oxidative stress increases in patients with IUGR. Providing high-risk patients with an antioxidant may be useful in the prevention or treatment of IUGR, although it is a condition with no certain treatment outcome. Copyright (c) 2007 S. Karger AG, Basel.